Check how incentives and vDOT help latent TB treatment
Part of Infections clinical trials.
This trial studies whether reminder-based “vDOT” and small economic incentives can help people complete treatment for latent (sleeping) tuberculosis. If you have latent TB and are starting a standard medicine plan, it may help you stay on track and finish safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with latent TB (not active TB) and your clinician says you should receive treatment
- You live in the Baltimore metro area
- You can take part in English, Spanish, or another language that has a short consent form available
- You are scheduled to take one of these standard latent TB regimens: 3 months isoniazid/rifapentine, 3 months isoniazid/rifampin, or 4 months rifampin
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with suspected or confirmed tuberculosis (TB), whether they have inactive “latent” TB or active TB. It helps researchers better understand TB’s natural course and may improve future testing and care by allowing collection and storage of samples.
This trial studies whether taking rifapentine every day is safe and helps prevent active tuberculosis (TB) in people who have latent TB infection. It aims to find the best way to stop TB from becoming a serious illness later.
This trial tests a very short (one-month) medicine course to prevent tuberculosis (TB) in students and school staff who have been exposed to someone with active TB. If you have latent TB infection (the germs are in your body but you're not sick), this treatment aims to stop it from turning into active TB disease.
This trial tests a shorter, safer treatment for people with latent TB infection (TB germs in your body but not making you sick). The goal is to prevent you from getting sick with active TB later.
This study tests ways to help people who live with or are close to someone with tuberculosis get medicine to prevent them from getting sick. It aims to improve how many people start and finish this preventive treatment in Tajikistan and Tanzania.
This study tests different treatment plans for people with tuberculosis (TB) that can be cured with standard medicines. It aims to find the best treatment for each person based on their risk score, which may lead to shorter or more effective treatment.
Hear when a new Latent Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.